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Background: Microphthalmia with linear skin defects (MLS) syndrome is a rare X-linked dominant male-lethal
developmental disorder characterized by unilateral or bilateral microphthalmia and linear skin defects of the face
and neck. Additional features affecting the eyes, heart, brain or genitourinary system can occur, corroborating the
intra- and interfamilial phenotypic variability. The majority of patients display monosomy of the Xp22.2 region,
where the holocytochrome c-type synthase (HCCS) gene is located.
Case presentation: We describe a 15-year-old-female affected by MLS syndrome and autism spectrum disorder
(ASD). ASD has not previously been reported as a component of MLS. Our patient shows a large deletion of
12.9 Mb, involving Xp22.32-p22.2, which encompasses both the HCCS gene and autism X-linked genes.
Conclusion: Thus, patients with a large deletion at Xp22 might display MLS with ASD, due to the deletion of
contiguous genes, although the highly variable phenotype of these patients could be influenced by several genetic
mechanisms, including different tissue-specific X-inactivation and somatic mosaicism.
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First described in 1988, the microphthalmia with linear
skin defects (MLS) syndrome (OMIM 309801) is also
known as MIDAS (Microphthalmia, Dermal Aplasia,
Sclerocornea) syndrome [1], but the MLS acronym is
more appropriate since dermal aplasia has never been de-
scribed in histologic samples [2]. This rare X-linked dom-
inant disease with male lethality in utero belongs to
neurocutaneous development disorders, and is character-
ized by unilateral or bilateral microphthalmia as well as
linear skin defects, along Blaschko lines, limited to the
face and neck. Most patients with MLS display the clas-
sical phenotypic features; however, a high intra- and inter-
familial clinical variability exists, and additional features* Correspondence: lucia.margari@uniba.it
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may be present [3].
Conventional and molecular cytogenetic studies of the
majority of patients with MLS syndrome have revealed
segmental monosomy of the Xp22 chromosomal region.
In particular, the MLS critical region has been identified
at 610 Kb in Xp22.2, and includes the holocytochrome
c-type synthase (HCCS) gene, encoding the mitochon-
drial holocytochrome c-type synthase, that is the gene
whose mutation is known to cause MLS syndrome [4,5].
Wimplinger et al. [5] detected that the final product of
HCSS activity is cytochrome c, which plays a key role in
apoptosis. Therefore HCCS mutations impair apoptosis,
leading to an abnormal eye and brain embryonic devel-
opment. It has been also hypothesized that a disturbance
of both the oxidative phosphorylation and the balance
between apoptosis and necrosis, as well as tissue specificl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Dysmorphic features in the patient. Physical
examination revealed areas of scar-like aplasia cutis following the
Blaschko lines along the cheek, nose and chin.
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phenotype [5].
Here we report the first case of MLS syndrome with
associated ASD features. Our patient shows a large dele-
tion involving Xpter-p22.2. The deletion encompasses
both the HCCS gene and several autism X-linked genes,
suggesting that large Xp deletions might be associated
with both MLS and ASD, probably due to the deletion
of contiguous genes. However, several genetic mecha-
nisms can influence the highly variable phenotype of this
exceedingly rare disorder.
Case presentation
The proband, a 15-year-old female, was born to a
28 year-old father and a 27 year-old mother. Her father
and sister are phenotypically normal. The mother pre-
sented a relatively short stature (cm 160), and corneal
degeneration, diagnosed at birth, for which she under-
went enucleation, and left eye prosthesis. Family history
was remarkable for not otherwise specified anxiety disor-
ders, and epilepsy in the maternal line.
An intrauterine growth restriction was revealed at the
22th gestational week. She was born at 38 weeks gestation
via emergency cesarean section, due to fetal distress. Birth
weight was 2.530 gr (10th centile), length 47 cm (10-50th
centile) and head circumference 33 cm (10-50th centile).
The Apgar scores were 7 and 8. Immediately after birth,
several life-threatening respiratory distress events occured,
requiring patient intubation. Slight asymmetry of the cere-
bral ventricles with hyperechogenicity of the parenchyma
on the superior-lateral horns of the lateral ventricles was
detected at ultrasound examination of the brain.
The newborn female showed linear and erythematous
skin lesions on the cheek, extending to the nose and
chin. Ophthalmologic evaluation revealed leukoma cor-
nea and microphthalmia of the right eye, and sclerocor-
nea and anophthalmia of the left. The clinical diagnosis
of the MLS syndrome was made.
Motor development was slightly delayed: she walked in-
dependently at 2 years of age, as commonly observed in
blind children, instead speech development was normal
until 18–24 months of age (she was able to speak simple
sentences), after that she started to show echolalia and
verbal stereotypy. At the age of 30 months, a further de-
terioration of language and cognitive abilities occurred,
with loss of previously acquired skills: expressive language
was limited to two-three single words, and unintelligible
verbalizations. She gradually developed seriously impaired
communication, socialization and cognition skills, as well
as sleep disturbances (difficulty falling asleep).
The patient was admitted to our department at the age
of 15 years, due to progressive social avoidance and
self-harm behaviors developing during the last year. Phys-
ical examination revealed skeletal abnormalities such asmicromelia, lower limb asymmetry, left scoliosis and pes
cavus bilaterally. Our patient had evident dysmorphic fea-
tures, including microcephaly (head circumference < 3rd
centile), flattened occiput, hypotelorism, low setting ears,
micrognathia, height and weight below the third percent-
ile, and a broad based gait. In addition, she showed areas
of scar-like aplasia cutis following the Blaschko lines along
the cheek, nose and chin (Figure 1). Neurologic examin-
ation showed diffuse hypotonia. An ophthalmologic evalu-
ation revealed right eye microphthalmia with opaque
cornea and left eye anophthalmia (with a prosthesis), with
total blindness in the left eye, and perception of light in
the right one.
Cardiac and otorinolaringoiatric examinations were nor-
mal, as well as auditory brainstem responses and asleep
electroencephalography. Brain magnetic resonance im-
aging showed a slight hyperintensity in the peritrigonal
white matter bilaterally, probably due to neonatal distress.
Routine blood tests, plasma amino acids, urine organic
acids and lactate were unremarkable.
Psychiatric and behavioral assessments, conducted by
direct observation of the patient’s spontaneous behavior,
revealed social withdrawal. Indeed, she preferred to be
alone, she did not turn around if her name was called,
and she did not respond to instructions and appeared
distant when attempts were made to interact with her.
She showed limited emotional non-verbal contact and
lacked social skills. Communication was limited to two-
three single words and vocalizations such as vowel
sounds or unintelligible verbalizations and failure to
compensate through gesture. She also showed stereo-
typic and repetitive motor mannerisms, many restricted,
ritualistic and “sameness” behaviors (e.g., listening to the
same music all the time), that were not due to visual im-
pairment. Moreover, she displayed self-harm tendencies
Figure 2 Array CGH analysis with a genomic resolution of 75
Kb showing a terminal microdeletion of about 12,9 Mb into
Xp22.2-pter region.
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tified in our patient were not due to visual impairment
and were confirmed by standardized rating scales includ-
ing the Childhood Autistic Rating Scale (CARS), Autism
Diagnostic Interview-Revised (ADI-R), Vineland Adap-
tive Behavior Scale. Indeed, on the CARS she scored 44
points (cut-off score 30), reflecting severe autism. The
diagnosis was confirmed by the ADI-R. The Vineland
Adaptive Behavior Scale showed severe deficits in adap-
tive behaviors. Her cognitive abilities were not assessed
using the standardized intelligence test because of the
severe blindness. However, empirical judgment sug-
gested moderate intellectual disability.
A diagnosis of the MLS syndrome with Autism Spectrum
Disorder (ASD) and moderate intellectual disability was
made, according to the Diagnostic and Statistical Manual of
Mental Disorders 5th Edition (DSM-V) criteria. Written in-
formed consent was obtained from the parent of the patient.
Genetic investigation
Genomic DNA was extracted from peripheral blood
samples. DNA concentration was measured by fluorim-
eter (Amersham, Piscataway, NJ) using the Hoechst re-
agent and adjusted to 400 ng/ml.
Array-CGH analysis was performed using the Cyto-
chip oligo ISCA 4x44K (Techno Genetics Srl, Italy). This
array is composed of 60-mer oligonucleotides spaced at
about 75 Kb density across the genome. Labeling and
hybridization were carried out following the manufac-
turer’s protocol. Slides were scanned on the InnoScan
710 (Innopsys), and analyzed using the BlueFuse Multi
v3.1 (Bluegnome). The analysis revealed a terminal dele-
tion of the short arm of chromosome X, with a loss in
copy number at the Xp22.33p22.2 region [chrX:702–
12,949,422 (hg19), size 12,948,721 bp] (Figure 2).
Result of array CGH analysis were confirmed by FISH.
BAC probes RP11-509B6, RP11-109P4, and RP11-102 M2
(Bluegnome), mapping in the deleted region, produced
hybridization signals only on the normal chromosome X.
The same deletion was revealed in the patient’s mother,
and confirmed by FISH analysis which also excluded
chromosomal mosaicism on interphase nuclei.
Therefore the final karyotype of the patient was de-
signed as (ISCN 2013): 46,XX.arr Xp22.33p22.2(702–
12,949,422)x1 mat.
X inactivation state was investigated using HUMARA
X-chromosome assay [6]. X-chromosome inactivation
was skewed, with preferential inactivation of the X
chromosome carrying the terminal deletion (ratio of 10%
to 90% in the proband; 15% to 85% in the mother).
Conclusion
In our patient, aCGH analysis has revealed a large ter-
minal deletion of 12,9 Mb (Xp22.2→Xp22.33), withproximal breakpoint at 12,949,422. The deletion was
confirmed by FISH; an identical imbalance was present
in the mother. The deletion involves 52 OMIM genes,
and is associated with several diseases.
In male patients, Xp deletions result in a contiguous
gene syndrome [7,8], and become lethal in utero when
extend beyond 9.7 Mb from Xpter [9], or include some
regions, i.e. the 610 Kb minimal critical region for MLS,
with loss of the HCSS gene [10]. Females with terminal
Xp deletions are characterized by a milder phenotype
with highly variable clinical manifestations, depending
on the size of the deletion as well as from other factors,
such as tissue specific X-inactivation patterns and/or
chromosomal mosaicism [4].
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proportionate short stature (< 3rd centile) and the skeletal
abnormalities to the loss of the SHOX gene, which is lo-
cated in the telomeric portion of the pseudoautosomal re-
gion 1 (PAR1). The gene is dose-dependent, and escape X
inactivation whereby its loss may cause Léri-Weill syn-
drome or non syndromic short stature [11].
In addition, in our case the loss of the Xp22.2 region
includes the genes MID1, HCCS, and ARHGAP6, and is
associated with MLS [1-3]. Our patient shows MLS
major criteria (right eye microphthalmia and left anoph-
thalmia, areas of scar-like aplasia cutis along the cheek,
nose and chin), and several minor criteria, namely right
cornea leukoma, left sclerocornea, developmental delay,
intellectual disability and dysmorphic features. The
mother, with the same deletion, shows a milder pheno-
type with left eye corneal degeneration as the only sign
attributable to MLS. Otherwise this is not surprising,
being well known in literature the very high intra- and
interfamilial variability of MLS [3,4,12]. Several mechan-
ism has been proposed. In some family chromosomal
mosaicism can account for the clinical variability [4].
However in our case such mechanism has been excluded
by FISH analysis, and X-inactivation in blood cells does
not explain the variable phenotype observed in the family.
Therefore, according to literature, different tissue specific
X-inactivation patterns seem the more plausible reason
for the mild vs severe mother/daughter phenotype [13,14].
Finally, a further, more peculiar, part of our patient
phenotype regards autistic behavioral features. Our
patient fulfilled DSM-V criteria for ASD on persistent
deficits in social communication and social interaction
across contexts and repetitive patterns of behavior, inter-
ests, or activities.
While developmental delay and intellectual disability
have been reported in a few patients, to the best of our
knowledge ASD has never previously been recognized in
MLS patients [3,15]. Differently large Xp deletions seem
associated with learning impairment and autistic tenden-
cies, even if the published cases are very rare, and a de-
tailed and thorough developmental assessment of ASD
has never been reported [10].
In particular Chocholska et al. [13] described a family
with an interstitial 7.7 Mb Xp22.2-22.3 deletion: the son
(III/2) showed autism and developmental delay. Hobson
et al. [10] reported a 20-year-old female with a terminal
Xp deletion very similar to our case (proximal break-
point at 12,024,000 bp) with short stature, MLS, moder-
ate learning difficulty associated with autistic traits
(obsessive behaviors, routines, lack of empathy). Further-
more autism, developmental delay, and dysmorphic fea-
tures were present in a 10-year-old patient with a de
novo interstitial Xp22 deletion extending from 5,005,810
to 10,556,218 bp [16].Therefore we can affirm that Xp22 region can play a piv-
otal role in the pathogenesis of autism, based on the pheno-
type of the rare patients with large Xp22 deletion as well as
on the presence of several genes potentially associated with
a behavioral phenotype that fits within the autism spectrum
disorder, i.e. NLGN4X, VCX genes [10,13,16-18]. NLGN
proteins are postsynaptic adhesion proteins, expressed in
brain, essential for synapse organization and function [19].
Mutations/haploinsufficiency of NLGN4X seem involved in
the pathogenesis of ASD [16,20], but it's not clear if such
role regards a limited fraction (<1%) of ASD patients or
NLGN4X variants could account for a more relevant role in
ASD [21]. VCX genes role in cognitive impairment has
been demonstrated; in addition these genes might contrib-
ute to the onset of neuropsychiatric illness, i.e. attention
deficit hyperactivity disorder [16]. Considering all these evi-
dences, we can assume that the presence of ASD seems re-
lated to the loss of the Xp22.32p22.31 region containing
NLGN4X/VCX genes, and not to the more proximal MLS
critical region. However further cases are needed to draw
more definitive issues.
In conclusion, the description of our case lends further
support to the notion that females with large deletions of
Xp or a 45,X constitution may be at increased risk of aut-
ism as the result of deletions of autism-linked genes [17],
indicating the need to carry out a detailed neuropsycho-
logical assessment in patients with MLS to check for ASD,
especially when MLS critical region haploinsufficiency oc-
curs in the context of a large Xp deletion. In these cases a
multi-disciplinary approach to the management of chil-
dren with the MLS syndrome is highly desirable. More-
over, genotype/phenotype correlation studies are needed
to better characterize the contribution of the individual
genes mapping in Xp22 to the autistic spectrum disorders.
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